Organon (OGN) Treasury Shares (2021 - 2026)
Organon (OGN) recorded quarterly Treasury Shares of $19.7 million in Q1 2026, up 102.79% quarter-over-quarter from $9.7 million in Q4 2025, and up 82.18% on a YoY basis from $10.8 million in Q1 2025.
Organon (OGN) Treasury Shares (2021 - 2026) Analysis & Trends
Organon's Treasury Shares history runs 6 years deep, the most recent figure standing at $19.7 million for Q1 2026.
- In Q1 2026, Treasury Shares rose 82.18% year-over-year to $19.7 million; the TTM figure through Mar 2026 stood at $19.7 million (up 82.18% YoY), while the FY2025 annual figure was $9.7 million, up 766.73% from the prior year.
- Treasury Shares was $19.7 million for Q1 2026 at Organon, up from $9.7 million in the prior quarter.
- In the past five years, Treasury Shares ranged from a high of $9.6 billion in Q1 2024 to a low of $120000.0 in Q1 2022.
- Historically, Treasury Shares has averaged $2.2 billion across 5 years, with a median of $486.0 million in 2022.
- The sharpest annual moves came in 2023 and 2025: Treasury Shares surged 6230733.33% in 2023, then slumped 99.99% in 2025.
- A 5-year view of Treasury Shares shows it stood at $486.0 million in 2022, then plunged by 99.77% to $1.1 million in 2023, then retreated by 0.09% to $1.1 million in 2024, then jumped by 766.73% to $9.7 million in 2025, then surged by 102.79% to $19.7 million in 2026.
- The last three Treasury Shares figures came in at $19.7 million (Q1 2026), $9.7 million (Q4 2025), and $9.7 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,026,132.38 Bn | 93,026,127.42 Bn | 7.76 Bn | - |
| 2 | Eli Lilly | 1,022.62 Bn | 1,017.34 Bn | 16.22 Bn | 3.01 Bn |
| 3 | Johnson & Johnson | 570.65 Bn | 548.59 Bn | 15.96 Bn | 713.26 Mn |
| 4 | AbbVie | 398.73 Bn | 389.38 Bn | 10.78 Bn | 77.08 Mn |
| 5 | Merck | 295.53 Bn | 289.88 Bn | 12.09 Bn | 1.11 Bn |
| 6 | Amgen | 186.30 Bn | 174.26 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 155.93 Bn | 148.21 Bn | 5.52 Bn | - |
| 8 | Pfizer | 146.09 Bn | 133.32 Bn | -1.21 Bn | 3.94 Bn |
| 9 | Bristol Myers Squibb | 114.98 Bn | 104.53 Bn | 8.07 Bn | 881.00 Mn |
| 10 | Organon | 3.49 Bn | 2.37 Bn | 783.00 Mn | 19.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 19.70 Mn |
| Mar 31, 2026 | 19.70 Mn |
| Dec 31, 2025 | 9.72 Mn |
| Dec 31, 2025 | 9.72 Mn |
| Sep 30, 2025 | 9.66 Mn |
| Sep 30, 2025 | 9.66 Mn |
| Jun 30, 2025 | 1.01 Mn |
| Jun 30, 2025 | 1.01 Mn |
| Mar 31, 2025 | 10.82 Mn |
| Mar 31, 2025 | 10.82 Mn |
| Dec 31, 2024 | 1.12 Mn |
| Dec 31, 2024 | 1.12 Mn |
| Sep 30, 2024 | 1.12 Bn |
| Sep 30, 2024 | 1.12 Bn |
| Jun 30, 2024 | 8.65 Bn |
| Jun 30, 2024 | 8.65 Bn |
| Mar 31, 2024 | 9.62 Bn |
| Mar 31, 2024 | 9.62 Bn |
| Dec 31, 2023 | 1.12 Mn |
| Dec 31, 2023 | 1.12 Mn |